- UroToday Home
- Recent Abstracts
- Urologic Oncology
Renal Cancer
Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach.
February 21, 2020
Development and validation of a prognostic immune-associated gene signature in clear cell renal cell carcinoma.
February 21, 2020
Comparative outcomes of radio frequency ablation versus partial nephrectomy for T1 renal tumors: a systematic review.
February 20, 2020
miR-124 and miR-203 synergistically inactivate EMT pathway via coregulation of ZEB2 in clear cell renal cell carcinoma (ccRCC).
February 20, 2020
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
February 20, 2020
Current State of Systemic Therapies for Advanced Renal Cell Carcinoma.
February 19, 2020
Long non-coding RNA TCL6 enhances preferential toxicity of paclitaxel to renal cell carcinoma cells.
February 19, 2020
Effect of m6A RNA Methylation Regulators on Malignant Progression and Prognosis in Renal Clear Cell Carcinoma.
February 18, 2020
Genome-wide Analysis of the Alternative Splicing Profiles Revealed Novel Prognostic Index for Kidney Renal Cell Clear Cell Carcinoma.
February 17, 2020
Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma.
February 17, 2020
Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
February 17, 2020
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.
February 14, 2020
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
February 14, 2020
Advancing serum peptidomic profiling by data-independent acquisition for clear-cell renal cell carcinoma detection and biomarker discovery.
February 14, 2020